ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
Read this article:
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
Related Post
- Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease - March 7th, 2021
- Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021 - March 7th, 2021
- Orion Corporation: Managers’ transactions – Jukka Ylppö - March 7th, 2021
- Transparency Notification - March 7th, 2021
- Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021 - March 7th, 2021
- Agile Therapeutics to Present at Upcoming March Investor Conferences - March 7th, 2021
- Tauriga Sciences Inc. Selects First Foods Group, Inc. to Manufacture its New, Full Spectrum CBD Infused Product Line - March 7th, 2021
- Imara Reports Full Year 2020 Financial Results and Business Highlights - March 7th, 2021
- Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET - March 7th, 2021
- DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - March 7th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 7th, 2021
- Lowell Farms Inc. Emerges From Acquisition With an Eye Toward Dominance in California’s Cannabis Industry and Beyond - March 7th, 2021
- Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team - March 7th, 2021
- AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement - March 7th, 2021
- Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections - March 7th, 2021
- Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection - March 7th, 2021
- Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021 - March 7th, 2021
- Immutep Expands Part B of TACTI-002 Study - March 5th, 2021
- Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial - March 5th, 2021
- Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference - March 5th, 2021
- Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to... - March 5th, 2021
- Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences - March 5th, 2021
- Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat... - March 5th, 2021
- Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market - March 5th, 2021
- Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd... - March 5th, 2021
- Novan to Present at the H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- MediPharm Labs Closes Previously Announced Bought Deal Equity Financing - March 5th, 2021
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced... - March 5th, 2021
- Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- Number of voting rights as of March 5, 2021 - March 5th, 2021
- Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19 - March 5th, 2021
- Bavarian Nordic to Host Full Year 2020 Results Conference Call - March 5th, 2021
- 22nd Century Group to Participate in Investor Conferences in March 2021 - March 5th, 2021
- Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021 - March 5th, 2021
- Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings - March 5th, 2021
- Vor Biopharma to Present at the Barclays Global Healthcare Conference - March 5th, 2021
- Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations - March 3rd, 2021
- TCR² Therapeutics to Participate in Two Upcoming Conferences in March - March 3rd, 2021
- Market Report Bodes Well for Reflect Scientific Growth Potential - March 3rd, 2021
- Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% - March 3rd, 2021
- Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating - March 3rd, 2021
- Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty - March 3rd, 2021
- Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors - March 3rd, 2021
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences - March 3rd, 2021
- Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - March 3rd, 2021
- Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer - March 3rd, 2021
- Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 - March 3rd, 2021
- Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - March 3rd, 2021
- Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Notice to convene Annual General Meeting - March 3rd, 2021
- Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference - March 3rd, 2021
- Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- 22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and... - March 3rd, 2021
- SetPoint Medical CEO Murthy Simhambhatla Named to AIMBE College of Fellows - March 3rd, 2021
- EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 - March 1st, 2021
- Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021 - March 1st, 2021
- MacroGenics to Participate in Upcoming Investor Conferences - March 1st, 2021
- Cronos Group Reports 2020 Fourth Quarter and Full-Year Results - March 1st, 2021
- GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis... - March 1st, 2021
- Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain - March 1st, 2021
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update - March 1st, 2021
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B... - March 1st, 2021
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - March 1st, 2021
- SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results - March 1st, 2021
- Molecular Templates to Participate in Upcoming Virtual Investor Conferences - March 1st, 2021
- ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American... - March 1st, 2021
- electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia - March 1st, 2021
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce... - March 1st, 2021
- Annual financial report 2020 - March 1st, 2021
- Idorsia submits NDA for clazosentan to Japanese PMDA - March 1st, 2021
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial - March 1st, 2021
- Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - March 1st, 2021
- Orphazyme appoints Christophe Bourdon as Chief Executive Officer - March 1st, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 27th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 27th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 27th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 27th, 2021
Recent Comments